Randomized PhaseII study of amrubicin vs platinum-doublet re-challenge for small cell lung cancer with sensitive relapse
Not Applicable
- Conditions
- Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000002617
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Pre-treated with amrubicin With severe co-morbidities With symptomatic brain metastasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method